Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future

Open access
Riley, R D, Abrams, K R, Sutton, A J, Lambert, P C, Jones, D R, Heney, D, Burchill, S A·2003·British Journal of Cancer

Abstract

Prognostic markers help to stratify patients for treatment by identifying patients with different risks of outcome (e.g. recurrence of disease), and are important tools in the management of cancer and many other diseases. Systematic review and meta-analytical approaches to identifying the most valuable prognostic markers are needed because (sometimes conflicting) evidence relating to markers is often published across a number of studies. To investigate the practicality of this approach, an empirical investigation of a systematic review of tumour markers for neuroblastoma was performed; 260 studies of prognostic markers were identified, which considered 130 different markers. The reporting of these studies was often inadequate, in terms of both statistical analysis and presentation, and there was considerable heterogeneity for many important clinical/statistical factors. These problems restricted both the extraction of data and the meta-analysis of results from the primary studies, limiting feasibility of the evidence-based approach.Guidelines for reporting the results of primary prognostic marker studies in cancer, and other diseases, are given in order to facilitate both the interpretation of individual studies and the undertaking of systematic reviews, meta-analysis and, ultimately, evidence-based practice. General availability of full individual patient data is a necessary step forward and would overcome the majority of problems encountered, including poorly reported summary statistics and variability in cutoff level, outcome assessed and adjustment factors used. It would also limit the problem of reporting bias, although publication bias will remain a concern until studies are prospectively registered. Such changes in practice would help important evidence-based reviews to be conducted in order to establish the most appropriate prognostic markers for clinical use, which should ultimately improve patient care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6600886

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 25

  1. Altman DG (2001) Systematic reviews of studies of prognostic variables. In Systematic Reviews in Health Care: Meta-analysis in Context, Egger M, Davey Smith G, Altman DG (eds) pp 228–247. London: BMJ Publishing Group · DOI
  2. Altman DG, De Stavola BL, Love SB, Stepniewska KA (1995) Review of survival analyses published in cancer journals. Br J Cancer 72: 511–518 · DOI · Paper page
  3. Berthold F, Sahin K, Hero B, Christiansen H, Gehring M, Harms D, Horz S, Lampert F, Schwab M, Terpe J (1997) The current contribution of molecular factors to risk estimation in neuroblastoma patients. Eur J Cancer 33(12): 2092–2097 · doi:10.1016/s0959-8049(97)00237-2
  4. Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C (1999) Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol 28(1): 1–9 · DOI · Paper page
  5. Duchateau L, Pignon JP, Bijnens L, Bertin S, Bourhis J, Sylvester R (2001) Individual patient-versus literature-based meta-analysis of survival data: time to event and event rate at a particular time can make a difference, an example based on head and neck cancer. Controlled Clin Trials 22(5): 538–547 · DOI
  6. Eche N, Pichon MF, Quillien V, Gory-Delabaere G, Riedinger JM, Basuyau JP, Daver A, Buecher B, Conroy T, Dieu L, Bidart JM, Deneux L (2001) Standards, options and recommendations for tumor markers in colorectal cancer. Bull Cancer 88(12): 1177–1206 [French]
  7. Fleiss JL, Gross AJ (1991) Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer: a critique. J Clin Epidemiol 44: 127–139 · DOI · Paper page
  8. Friedberg B, Watine J, Miedouge M (2001) Unresected colorectal liver metastases: prognostic value of laboratory variables. Gastroenterol Clin Biol 25(11): 962–966
  9. Hutchon DJR (2001) Publishing raw data and real time statistical analysis on e-journals. Br Med J 322(7285): 530 · DOI
  10. Lambert PC, Sutton AJ, Abrams KR, Jones DR (2002) A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol 55(1): 86–94 · DOI · Paper page
  11. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broet P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Janicke F, Schmitt M, Foekens JA (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94(2): 116–128 · DOI · Paper page
  12. Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS, Hogarty MD, Sulman EP, Thompson PM, Lukens JN, Matthay KK, Seeger RC, Brodeur GM (2000) Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol 18(9): 1888–1899 · DOI · Paper page
  13. Mott MG, Mann JR, Stiller CA (1997) The United Kingdom Children's Cancer Study Group – the first 20 years of growth and development. Eur J Cancer 33(9): 1448–1452 · DOI
  14. Parker CC, Gospodarowicz M, Warde P (2001) Does age influence the behaviour of localized prostate cancer? BJU Int 87: 629–637 · DOI
  15. Parmar MKB, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815–2834 · DOI · Paper page
  16. Riley RD, Burchill SA, Abrams KR, Heney D, Sutton AJ, Jones DR, Lambert PC, Young B, Wailoo AJ, Lewis IJ (2003a) A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family. Eur J Cancer 39: 19–30 · DOI
  17. Riley RD, Burchill SA, Abrams KR, Heney D, Lambert PC, Jones DR, Sutton AJ, Young B, Wailoo AJ, Lewis IJ (2003b) Systematic review Q2and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma. NHS Health Technology Assessment (No. 97/15/03) 2003. Vol. 7, No. 5 · DOI · Paper page
  18. Rushton L, Jones DR (1992) Oral contraceptive use and breast cancer risk: a meta-analysis of variations with age at diagnosis, parity and total duration of oral contraceptive use. Br J Obstet Gynaecol 99: 239–246 · DOI
  19. Sakamoto J, Teramukai S, Koike A, Saji S, Ohashi Y, Nakazato H (1996) Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma. Findings from three independent clinical trials. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer. Cancer 77(11): 2206–2212. · doi:10.1002/(sici)1097-0142(19960601)77:11<2206::aid-cncr4>3.0.co;2-n
  20. Sauerbrei W, Royston P, Bojar H, Schmoor C, Schumacher M (1999) Modelling the effects of standard prognostic factors in node-positive breast cancer. German Breast Cancer Study Group (GBSG). Br J Cancer 79(11–12): 1752–1760 · DOI
  21. Stewart LA, Clarke MJ (1995) Practical methodology of meta-analyses (overviews) using individual patient data. Cochrane Working Group. Stat Med 14: 2057–2079 · DOI · Paper page
  22. Stewart LA, Parmar MKB (1993) Meta-analysis of the literature or of individual patient data: is there a difference? The Lancet 341: 418–422 · DOI · Paper page
  23. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F (2000) Methods for Meta-analysis in Medical Research. London: John Wiley
  24. Vale CL, Tierney JF, Stewart LA (2002) Effects of adjusting for censoring on meta-analyses of time-to-event outcomes. Int J Epidemiol 31(1): 107–111 · DOI
  25. Zandbergen EGJ, de Haan RJ, Hijdra A (2001) Systematic review of prediction of poor outcome in anoxic-ischaemic coma with biochemical markers of brain damage. Intens Care Med 27: 1661–1667 · doi:10.1007/s001340101076

Cited by

See all 166

Metadata

Authors
Riley, R. D., Abrams, K. R., Sutton, A. J., Lambert, P. C., Jones, D. R., Heney, D., & Burchill, S. A.
Venue
British Journal of Cancer
Published
2003-04
Volume
88
Issue
8
Pages
1191-1198
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2077523260
Cited by
166
References
3
FWCI
12.20
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. https://app.cochat.ai/papers/10.1038/sj.bjc.6600886
The paper
Riley, R. D., Abrams, K. R., Sutton, A. J., Lambert, P. C., Jones, D. R., Heney, D., & Burchill, S. A. (2003). Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6600886

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.